nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Idarubicin—breast cancer	0.135	0.702	CrCtD
Epirubicin—Anthracyclines—Idarubicin—breast cancer	0.0823	0.327	CiPCiCtD
Epirubicin—bone cancer—breast cancer	0.0734	0.531	CtDrD
Epirubicin—ovarian cancer—breast cancer	0.0648	0.469	CtDrD
Epirubicin—Doxorubicin—breast cancer	0.0574	0.298	CrCtD
Epirubicin—Topoisomerase Inhibitors—Idarubicin—breast cancer	0.043	0.171	CiPCiCtD
Epirubicin—AURKA—breast cancer	0.0429	0.39	CbGaD
Epirubicin—Topoisomerase Inhibitors—Irinotecan—breast cancer	0.0366	0.145	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Mitoxantrone—breast cancer	0.0366	0.145	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—breast cancer	0.035	0.139	CiPCiCtD
Epirubicin—Doxorubicin—Idarubicin—breast cancer	0.0289	0.234	CrCrCtD
Epirubicin—Daunorubicin—Idarubicin—breast cancer	0.0289	0.234	CrCrCtD
Epirubicin—Valrubicin—Idarubicin—breast cancer	0.0289	0.234	CrCrCtD
Epirubicin—DHCR7—Tamoxifen—breast cancer	0.0282	0.265	CbGbCtD
Epirubicin—PLA2G4A—breast cancer	0.0277	0.251	CbGaD
Epirubicin—ABCC1—breast cancer	0.0223	0.203	CbGaD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—breast cancer	0.0183	0.0726	CiPCiCtD
Epirubicin—TOP2A—breast cancer	0.0172	0.156	CbGaD
Epirubicin—TOP2A—Idarubicin—breast cancer	0.013	0.122	CbGbCtD
Epirubicin—Daunorubicin—Doxorubicin—breast cancer	0.0123	0.0994	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—breast cancer	0.0123	0.0994	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—breast cancer	0.0123	0.0994	CrCrCtD
Epirubicin—YWHAG—Doxorubicin—breast cancer	0.0118	0.111	CbGbCtD
Epirubicin—DHCR7—Doxorubicin—breast cancer	0.0118	0.111	CbGbCtD
Epirubicin—AURKA—Doxorubicin—breast cancer	0.0118	0.111	CbGbCtD
Epirubicin—ABCC1—Idarubicin—breast cancer	0.00721	0.0676	CbGbCtD
Epirubicin—TOP2A—Mitoxantrone—breast cancer	0.00559	0.0525	CbGbCtD
Epirubicin—ABCC1—Mitoxantrone—breast cancer	0.0031	0.0291	CbGbCtD
Epirubicin—ABCC1—Paclitaxel—breast cancer	0.00247	0.0232	CbGbCtD
Epirubicin—ABCC1—Irinotecan—breast cancer	0.00244	0.0229	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—breast cancer	0.00241	0.0226	CbGbCtD
Epirubicin—ABCC1—Vinblastine—breast cancer	0.00217	0.0204	CbGbCtD
Epirubicin—ABCC1—Docetaxel—breast cancer	0.00179	0.0168	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—breast cancer	0.00133	0.0125	CbGbCtD
Epirubicin—ABCC1—Methotrexate—breast cancer	0.00129	0.0121	CbGbCtD
Epirubicin—CHD1—mammary gland—breast cancer	0.000565	0.0457	CbGeAlD
Epirubicin—CHD1—nipple—breast cancer	0.000468	0.0378	CbGeAlD
Epirubicin—AURKA—mammary gland—breast cancer	0.000456	0.0368	CbGeAlD
Epirubicin—DHCR7—mammary gland—breast cancer	0.000381	0.0308	CbGeAlD
Epirubicin—YWHAG—mammary gland—breast cancer	0.00035	0.0283	CbGeAlD
Epirubicin—DHCR7—nipple—breast cancer	0.000315	0.0255	CbGeAlD
Epirubicin—YWHAG—nipple—breast cancer	0.000289	0.0234	CbGeAlD
Epirubicin—CHD1—endometrium—breast cancer	0.000282	0.0228	CbGeAlD
Epirubicin—CHD1—uterus—breast cancer	0.00026	0.021	CbGeAlD
Epirubicin—CHD1—pituitary gland—breast cancer	0.000255	0.0206	CbGeAlD
Epirubicin—CHD1—adipose tissue—breast cancer	0.000254	0.0206	CbGeAlD
Epirubicin—CHD1—female reproductive system—breast cancer	0.000234	0.0189	CbGeAlD
Epirubicin—CHD1—adrenal gland—breast cancer	0.000228	0.0184	CbGeAlD
Epirubicin—AURKA—endometrium—breast cancer	0.000228	0.0184	CbGeAlD
Epirubicin—CHD1—bone marrow—breast cancer	0.000221	0.0178	CbGeAlD
Epirubicin—PLA2G4A—nipple—breast cancer	0.000216	0.0174	CbGeAlD
Epirubicin—CHD1—female gonad—breast cancer	0.000213	0.0172	CbGeAlD
Epirubicin—AURKA—uterus—breast cancer	0.00021	0.0169	CbGeAlD
Epirubicin—AURKA—pituitary gland—breast cancer	0.000206	0.0166	CbGeAlD
Epirubicin—TOP2A—nipple—breast cancer	0.000205	0.0166	CbGeAlD
Epirubicin—DHCR7—skin of body—breast cancer	0.000202	0.0163	CbGeAlD
Epirubicin—CHD1—endocrine gland—breast cancer	0.000198	0.016	CbGeAlD
Epirubicin—AURKA—female reproductive system—breast cancer	0.000189	0.0152	CbGeAlD
Epirubicin—AURKA—adrenal gland—breast cancer	0.000184	0.0149	CbGeAlD
Epirubicin—Doxorubicin—NDUFS3—breast cancer	0.000182	0.177	CrCbGaD
Epirubicin—AURKA—bone marrow—breast cancer	0.000178	0.0144	CbGeAlD
Epirubicin—YWHAG—endometrium—breast cancer	0.000175	0.0141	CbGeAlD
Epirubicin—DHCR7—pituitary gland—breast cancer	0.000172	0.0139	CbGeAlD
Epirubicin—DHCR7—adipose tissue—breast cancer	0.000172	0.0139	CbGeAlD
Epirubicin—AURKA—female gonad—breast cancer	0.000172	0.0139	CbGeAlD
Epirubicin—YWHAG—uterus—breast cancer	0.000161	0.013	CbGeAlD
Epirubicin—AURKA—endocrine gland—breast cancer	0.00016	0.0129	CbGeAlD
Epirubicin—YWHAG—pituitary gland—breast cancer	0.000158	0.0128	CbGeAlD
Epirubicin—DHCR7—female reproductive system—breast cancer	0.000158	0.0127	CbGeAlD
Epirubicin—YWHAG—adipose tissue—breast cancer	0.000157	0.0127	CbGeAlD
Epirubicin—DHCR7—adrenal gland—breast cancer	0.000154	0.0124	CbGeAlD
Epirubicin—DHCR7—bone marrow—breast cancer	0.000149	0.012	CbGeAlD
Epirubicin—YWHAG—female reproductive system—breast cancer	0.000145	0.0117	CbGeAlD
Epirubicin—DHCR7—female gonad—breast cancer	0.000144	0.0116	CbGeAlD
Epirubicin—YWHAG—adrenal gland—breast cancer	0.000141	0.0114	CbGeAlD
Epirubicin—CHD1—lymph node—breast cancer	0.000137	0.0111	CbGeAlD
Epirubicin—YWHAG—bone marrow—breast cancer	0.000137	0.011	CbGeAlD
Epirubicin—DHCR7—endocrine gland—breast cancer	0.000133	0.0108	CbGeAlD
Epirubicin—YWHAG—female gonad—breast cancer	0.000132	0.0106	CbGeAlD
Epirubicin—UGT2B7—female reproductive system—breast cancer	0.000131	0.0106	CbGeAlD
Epirubicin—PLA2G4A—endometrium—breast cancer	0.00013	0.0105	CbGeAlD
Epirubicin—CHD1—Topotecan—Irinotecan—breast cancer	0.000128	0.171	CbGdCrCtD
Epirubicin—TOP2A—endometrium—breast cancer	0.000124	0.01	CbGeAlD
Epirubicin—ABCC1—nipple—breast cancer	0.000123	0.00997	CbGeAlD
Epirubicin—YWHAG—endocrine gland—breast cancer	0.000122	0.00989	CbGeAlD
Epirubicin—Valrubicin—TOP2A—breast cancer	0.000122	0.118	CrCbGaD
Epirubicin—PLA2G4A—pituitary gland—breast cancer	0.000118	0.00952	CbGeAlD
Epirubicin—PLA2G4A—adipose tissue—breast cancer	0.000117	0.00949	CbGeAlD
Epirubicin—TOP2A—uterus—breast cancer	0.000114	0.00921	CbGeAlD
Epirubicin—TOP2A—adipose tissue—breast cancer	0.000112	0.00901	CbGeAlD
Epirubicin—UGT2B7—endocrine gland—breast cancer	0.000111	0.00893	CbGeAlD
Epirubicin—AURKA—lymph node—breast cancer	0.00011	0.00891	CbGeAlD
Epirubicin—PLA2G4A—female reproductive system—breast cancer	0.000108	0.00872	CbGeAlD
Epirubicin—PLA2G4A—adrenal gland—breast cancer	0.000105	0.00851	CbGeAlD
Epirubicin—PLA2G4A—bone marrow—breast cancer	0.000102	0.00823	CbGeAlD
Epirubicin—TOP2A—adrenal gland—breast cancer	0.0001	0.00808	CbGeAlD
Epirubicin—PLA2G4A—female gonad—breast cancer	9.82e-05	0.00793	CbGeAlD
Epirubicin—TOP2A—bone marrow—breast cancer	9.68e-05	0.00782	CbGeAlD
Epirubicin—TOP2A—female gonad—breast cancer	9.33e-05	0.00754	CbGeAlD
Epirubicin—DHCR7—lymph node—breast cancer	9.23e-05	0.00745	CbGeAlD
Epirubicin—PLA2G4A—endocrine gland—breast cancer	9.13e-05	0.00738	CbGeAlD
Epirubicin—Idarubicin—ABCC1—breast cancer	9.06e-05	0.0881	CrCbGaD
Epirubicin—YWHAG—lymph node—breast cancer	8.46e-05	0.00684	CbGeAlD
Epirubicin—Doxorubicin—AURKA—breast cancer	7.57e-05	0.0737	CrCbGaD
Epirubicin—ABCC1—endometrium—breast cancer	7.45e-05	0.00602	CbGeAlD
Epirubicin—AURKA—Chlorambucil—Melphalan—breast cancer	7.28e-05	0.0971	CbGdCrCtD
Epirubicin—Idarubicin—TOP2A—breast cancer	6.99e-05	0.068	CrCbGaD
Epirubicin—ABCC1—uterus—breast cancer	6.87e-05	0.00555	CbGeAlD
Epirubicin—ABCC1—pituitary gland—breast cancer	6.74e-05	0.00545	CbGeAlD
Epirubicin—ABCC1—adipose tissue—breast cancer	6.72e-05	0.00543	CbGeAlD
Epirubicin—CHD1—Daunorubicin—Idarubicin—breast cancer	6.54e-05	0.0873	CbGdCrCtD
Epirubicin—CHD1—Doxorubicin—Idarubicin—breast cancer	6.54e-05	0.0873	CbGdCrCtD
Epirubicin—PLA2G4A—lymph node—breast cancer	6.31e-05	0.0051	CbGeAlD
Epirubicin—ABCC1—adrenal gland—breast cancer	6.03e-05	0.00487	CbGeAlD
Epirubicin—TOP2A—lymph node—breast cancer	6e-05	0.00485	CbGeAlD
Epirubicin—ABCC1—female gonad—breast cancer	5.62e-05	0.00454	CbGeAlD
Epirubicin—Daunorubicin—ABCC1—breast cancer	4.86e-05	0.0473	CrCbGaD
Epirubicin—PLA2G4A—Estradiol—Fulvestrant—breast cancer	4.45e-05	0.0594	CbGdCrCtD
Epirubicin—Doxorubicin—NQO1—breast cancer	4.35e-05	0.0423	CrCbGaD
Epirubicin—AURKA—Topotecan—Irinotecan—breast cancer	4.2e-05	0.0561	CbGdCrCtD
Epirubicin—Doxorubicin—ABCC1—breast cancer	3.94e-05	0.0384	CrCbGaD
Epirubicin—Daunorubicin—TOP2A—breast cancer	3.75e-05	0.0365	CrCbGaD
Epirubicin—Daunorubicin—CYP1B1—breast cancer	3.71e-05	0.0361	CrCbGaD
Epirubicin—Doxorubicin—NOS3—breast cancer	3.67e-05	0.0357	CrCbGaD
Epirubicin—ABCC1—lymph node—breast cancer	3.61e-05	0.00292	CbGeAlD
Epirubicin—Doxorubicin—NOS2—breast cancer	3.54e-05	0.0345	CrCbGaD
Epirubicin—Doxorubicin—TOP2A—breast cancer	3.04e-05	0.0296	CrCbGaD
Epirubicin—Doxorubicin—CYP1B1—breast cancer	3.01e-05	0.0293	CrCbGaD
Epirubicin—Idarubicin—CYP2D6—breast cancer	2.78e-05	0.0271	CrCbGaD
Epirubicin—CHD1—Idarubicin—Doxorubicin—breast cancer	2.78e-05	0.0371	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—breast cancer	2.78e-05	0.0371	CbGdCrCtD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—breast cancer	2.67e-05	0.0356	CbGdCrCtD
Epirubicin—Daunorubicin—ABCG2—breast cancer	2.56e-05	0.0249	CrCbGaD
Epirubicin—TOP2A—Docetaxel—Paclitaxel—breast cancer	2.26e-05	0.0301	CbGdCrCtD
Epirubicin—TOP2A—Gefitinib—Lapatinib—breast cancer	2.21e-05	0.0295	CbGdCrCtD
Epirubicin—AURKA—Doxorubicin—Idarubicin—breast cancer	2.15e-05	0.0287	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Idarubicin—breast cancer	2.15e-05	0.0287	CbGdCrCtD
Epirubicin—Doxorubicin—ABCG2—breast cancer	2.08e-05	0.0202	CrCbGaD
Epirubicin—Daunorubicin—CYP1A1—breast cancer	2e-05	0.0195	CrCbGaD
Epirubicin—TOP2A—Topotecan—Irinotecan—breast cancer	1.61e-05	0.0214	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vinorelbine—breast cancer	1.44e-05	0.0192	CbGdCrCtD
Epirubicin—Daunorubicin—CYP3A4—breast cancer	1.28e-05	0.0125	CrCbGaD
Epirubicin—Doxorubicin—CYP2D6—breast cancer	1.21e-05	0.0118	CrCbGaD
Epirubicin—TOP2A—Vindesine—Vinblastine—breast cancer	1.15e-05	0.0153	CbGdCrCtD
Epirubicin—TOP2A—Paclitaxel—Docetaxel—breast cancer	1.13e-05	0.015	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Gemcitabine—breast cancer	1.07e-05	0.0142	CbGdCrCtD
Epirubicin—Daunorubicin—ABCB1—breast cancer	1.07e-05	0.0104	CrCbGaD
Epirubicin—Doxorubicin—CYP3A4—breast cancer	1.04e-05	0.0101	CrCbGaD
Epirubicin—AURKA—Idarubicin—Doxorubicin—breast cancer	9.14e-06	0.0122	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—breast cancer	9.14e-06	0.0122	CbGdCrCtD
Epirubicin—Doxorubicin—ABCB1—breast cancer	8.65e-06	0.00842	CrCbGaD
Epirubicin—TOP2A—Doxorubicin—Idarubicin—breast cancer	8.22e-06	0.011	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Idarubicin—breast cancer	8.22e-06	0.011	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinorelbine—breast cancer	7.74e-06	0.0103	CbGdCrCtD
Epirubicin—TOP2A—Vinorelbine—Vinblastine—breast cancer	7.24e-06	0.00966	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Fluoxymesterone—breast cancer	6.36e-06	0.00849	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Fluoxymesterone—breast cancer	6.36e-06	0.00849	CbGdCrCtD
Epirubicin—TOP2A—Vinblastine—Vinorelbine—breast cancer	6.23e-06	0.00831	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinblastine—breast cancer	6.19e-06	0.00826	CbGdCrCtD
Epirubicin—TOP2A—Methyltestosterone—Fluoxymesterone—breast cancer	5.21e-06	0.00696	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Gemcitabine—breast cancer	4.07e-06	0.00543	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—breast cancer	3.49e-06	0.00466	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—breast cancer	3.49e-06	0.00466	CbGdCrCtD
Epirubicin—TOP2A—Norethindrone—Fluoxymesterone—breast cancer	3.4e-06	0.00454	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Gemcitabine—breast cancer	2.92e-06	0.00389	CbGdCrCtD
Epirubicin—Urinary tract infection—Doxorubicin—breast cancer	2.27e-06	5.32e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Capecitabine—breast cancer	2.27e-06	5.31e-05	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—breast cancer	2.27e-06	5.31e-05	CcSEcCtD
Epirubicin—Diarrhoea—Fluorouracil—breast cancer	2.27e-06	5.3e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Capecitabine—breast cancer	2.27e-06	5.3e-05	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—breast cancer	2.26e-06	5.29e-05	CcSEcCtD
Epirubicin—Tachycardia—Capecitabine—breast cancer	2.26e-06	5.29e-05	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—breast cancer	2.25e-06	5.27e-05	CcSEcCtD
Epirubicin—Skin disorder—Capecitabine—breast cancer	2.25e-06	5.26e-05	CcSEcCtD
Epirubicin—Sweating—Doxorubicin—breast cancer	2.24e-06	5.25e-05	CcSEcCtD
Epirubicin—Urticaria—Paclitaxel—breast cancer	2.24e-06	5.24e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Capecitabine—breast cancer	2.24e-06	5.24e-05	CcSEcCtD
Epirubicin—Hypotension—Docetaxel—breast cancer	2.23e-06	5.23e-05	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—breast cancer	2.23e-06	5.22e-05	CcSEcCtD
Epirubicin—Abdominal pain—Paclitaxel—breast cancer	2.23e-06	5.22e-05	CcSEcCtD
Epirubicin—Body temperature increased—Paclitaxel—breast cancer	2.23e-06	5.22e-05	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—breast cancer	2.21e-06	5.18e-05	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—breast cancer	2.21e-06	5.16e-05	CcSEcCtD
Epirubicin—Anorexia—Capecitabine—breast cancer	2.21e-06	5.16e-05	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—breast cancer	2.2e-06	5.15e-05	CcSEcCtD
Epirubicin—Vomiting—Irinotecan—breast cancer	2.2e-06	5.15e-05	CcSEcCtD
Epirubicin—Vomiting—Mitoxantrone—breast cancer	2.2e-06	5.15e-05	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—breast cancer	2.19e-06	5.14e-05	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—breast cancer	2.19e-06	5.13e-05	CcSEcCtD
Epirubicin—Dizziness—Fluorouracil—breast cancer	2.19e-06	5.13e-05	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—breast cancer	2.18e-06	5.12e-05	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—breast cancer	2.18e-06	5.11e-05	CcSEcCtD
Epirubicin—Rash—Mitoxantrone—breast cancer	2.18e-06	5.1e-05	CcSEcCtD
Epirubicin—Rash—Irinotecan—breast cancer	2.18e-06	5.1e-05	CcSEcCtD
Epirubicin—Dermatitis—Mitoxantrone—breast cancer	2.18e-06	5.1e-05	CcSEcCtD
Epirubicin—Dermatitis—Irinotecan—breast cancer	2.18e-06	5.1e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Docetaxel—breast cancer	2.18e-06	5.1e-05	CcSEcCtD
Epirubicin—Chills—Methotrexate—breast cancer	2.18e-06	5.09e-05	CcSEcCtD
Epirubicin—Headache—Mitoxantrone—breast cancer	2.17e-06	5.07e-05	CcSEcCtD
Epirubicin—Headache—Irinotecan—breast cancer	2.17e-06	5.07e-05	CcSEcCtD
Epirubicin—Hypotension—Capecitabine—breast cancer	2.16e-06	5.06e-05	CcSEcCtD
Epirubicin—Insomnia—Docetaxel—breast cancer	2.16e-06	5.06e-05	CcSEcCtD
Epirubicin—Paraesthesia—Docetaxel—breast cancer	2.15e-06	5.02e-05	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—breast cancer	2.14e-06	5.02e-05	CcSEcCtD
Epirubicin—Vomiting—Gemcitabine—breast cancer	2.14e-06	5.01e-05	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—breast cancer	2.14e-06	5e-05	CcSEcCtD
Epirubicin—Dyspnoea—Docetaxel—breast cancer	2.13e-06	4.99e-05	CcSEcCtD
Epirubicin—Somnolence—Docetaxel—breast cancer	2.12e-06	4.97e-05	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—breast cancer	2.12e-06	4.97e-05	CcSEcCtD
Epirubicin—Rash—Gemcitabine—breast cancer	2.12e-06	4.97e-05	CcSEcCtD
Epirubicin—Dermatitis—Gemcitabine—breast cancer	2.12e-06	4.97e-05	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—breast cancer	2.11e-06	4.94e-05	CcSEcCtD
Epirubicin—Erythema—Methotrexate—breast cancer	2.11e-06	4.94e-05	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—breast cancer	2.11e-06	4.94e-05	CcSEcCtD
Epirubicin—Headache—Gemcitabine—breast cancer	2.11e-06	4.94e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Capecitabine—breast cancer	2.11e-06	4.94e-05	CcSEcCtD
Epirubicin—Vomiting—Fluorouracil—breast cancer	2.11e-06	4.93e-05	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—breast cancer	2.1e-06	4.93e-05	CcSEcCtD
Epirubicin—Dyspepsia—Docetaxel—breast cancer	2.1e-06	4.93e-05	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—breast cancer	2.1e-06	4.92e-05	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—breast cancer	2.1e-06	4.92e-05	CcSEcCtD
Epirubicin—Insomnia—Capecitabine—breast cancer	2.09e-06	4.9e-05	CcSEcCtD
Epirubicin—Hypoaesthesia—Doxorubicin—breast cancer	2.09e-06	4.89e-05	CcSEcCtD
Epirubicin—Rash—Fluorouracil—breast cancer	2.09e-06	4.89e-05	CcSEcCtD
Epirubicin—Dermatitis—Fluorouracil—breast cancer	2.09e-06	4.88e-05	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—breast cancer	2.08e-06	4.88e-05	CcSEcCtD
Epirubicin—Paraesthesia—Capecitabine—breast cancer	2.08e-06	4.86e-05	CcSEcCtD
Epirubicin—Decreased appetite—Docetaxel—breast cancer	2.08e-06	4.86e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Paclitaxel—breast cancer	2.08e-06	4.86e-05	CcSEcCtD
Epirubicin—Headache—Fluorouracil—breast cancer	2.07e-06	4.86e-05	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—breast cancer	2.07e-06	4.85e-05	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—breast cancer	2.07e-06	4.84e-05	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—breast cancer	2.07e-06	4.84e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Docetaxel—breast cancer	2.06e-06	4.83e-05	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—breast cancer	2.06e-06	4.83e-05	CcSEcCtD
Epirubicin—Dyspnoea—Capecitabine—breast cancer	2.06e-06	4.83e-05	CcSEcCtD
Epirubicin—Fatigue—Docetaxel—breast cancer	2.06e-06	4.82e-05	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—breast cancer	2.06e-06	4.82e-05	CcSEcCtD
Epirubicin—Nausea—Irinotecan—breast cancer	2.05e-06	4.81e-05	CcSEcCtD
Epirubicin—Nausea—Mitoxantrone—breast cancer	2.05e-06	4.81e-05	CcSEcCtD
Epirubicin—Pain—Docetaxel—breast cancer	2.04e-06	4.79e-05	CcSEcCtD
Epirubicin—Constipation—Docetaxel—breast cancer	2.04e-06	4.79e-05	CcSEcCtD
Epirubicin—Back pain—Methotrexate—breast cancer	2.04e-06	4.78e-05	CcSEcCtD
Epirubicin—Dyspepsia—Capecitabine—breast cancer	2.04e-06	4.77e-05	CcSEcCtD
Epirubicin—Visual impairment—Doxorubicin—breast cancer	2.02e-06	4.74e-05	CcSEcCtD
Epirubicin—Asthenia—Paclitaxel—breast cancer	2.02e-06	4.74e-05	CcSEcCtD
Epirubicin—Decreased appetite—Capecitabine—breast cancer	2.01e-06	4.71e-05	CcSEcCtD
Epirubicin—Nausea—Gemcitabine—breast cancer	2e-06	4.68e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Capecitabine—breast cancer	2e-06	4.68e-05	CcSEcCtD
Epirubicin—Fatigue—Capecitabine—breast cancer	1.99e-06	4.67e-05	CcSEcCtD
Epirubicin—Pruritus—Paclitaxel—breast cancer	1.99e-06	4.67e-05	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—breast cancer	1.99e-06	4.66e-05	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—breast cancer	1.98e-06	4.65e-05	CcSEcCtD
Epirubicin—Constipation—Capecitabine—breast cancer	1.98e-06	4.63e-05	CcSEcCtD
Epirubicin—Pain—Capecitabine—breast cancer	1.98e-06	4.63e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Docetaxel—breast cancer	1.97e-06	4.61e-05	CcSEcCtD
Epirubicin—Nausea—Fluorouracil—breast cancer	1.97e-06	4.61e-05	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—breast cancer	1.96e-06	4.59e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—breast cancer	1.96e-06	4.59e-05	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—breast cancer	1.96e-06	4.58e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Docetaxel—breast cancer	1.95e-06	4.58e-05	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—breast cancer	1.95e-06	4.57e-05	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—breast cancer	1.95e-06	4.56e-05	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—breast cancer	1.95e-06	4.56e-05	CcSEcCtD
Epirubicin—Diarrhoea—Paclitaxel—breast cancer	1.93e-06	4.52e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Capecitabine—breast cancer	1.91e-06	4.46e-05	CcSEcCtD
Epirubicin—Angiopathy—Doxorubicin—breast cancer	1.9e-06	4.46e-05	CcSEcCtD
Epirubicin—Malaise—Methotrexate—breast cancer	1.9e-06	4.46e-05	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—breast cancer	1.9e-06	4.44e-05	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—breast cancer	1.9e-06	4.44e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Capecitabine—breast cancer	1.89e-06	4.43e-05	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—breast cancer	1.89e-06	4.43e-05	CcSEcCtD
Epirubicin—Body temperature increased—Docetaxel—breast cancer	1.89e-06	4.42e-05	CcSEcCtD
Epirubicin—Abdominal pain—Docetaxel—breast cancer	1.89e-06	4.42e-05	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—breast cancer	1.89e-06	4.42e-05	CcSEcCtD
Epirubicin—Chills—Doxorubicin—breast cancer	1.88e-06	4.41e-05	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—breast cancer	1.88e-06	4.39e-05	CcSEcCtD
Epirubicin—Dizziness—Paclitaxel—breast cancer	1.86e-06	4.37e-05	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—breast cancer	1.85e-06	4.34e-05	CcSEcCtD
Epirubicin—Cough—Methotrexate—breast cancer	1.84e-06	4.31e-05	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—breast cancer	1.84e-06	4.31e-05	CcSEcCtD
Epirubicin—Urticaria—Capecitabine—breast cancer	1.84e-06	4.3e-05	CcSEcCtD
Epirubicin—Abdominal pain—Capecitabine—breast cancer	1.83e-06	4.28e-05	CcSEcCtD
Epirubicin—Body temperature increased—Capecitabine—breast cancer	1.83e-06	4.28e-05	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—breast cancer	1.83e-06	4.28e-05	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—breast cancer	1.83e-06	4.28e-05	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—breast cancer	1.83e-06	4.28e-05	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—breast cancer	1.8e-06	4.22e-05	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—breast cancer	1.8e-06	4.21e-05	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—breast cancer	1.8e-06	4.21e-05	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—breast cancer	1.8e-06	4.21e-05	CcSEcCtD
Epirubicin—Tension—Doxorubicin—breast cancer	1.79e-06	4.2e-05	CcSEcCtD
Epirubicin—Vomiting—Paclitaxel—breast cancer	1.79e-06	4.2e-05	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—breast cancer	1.79e-06	4.19e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.78e-06	4.18e-05	CcSEcCtD
Epirubicin—Rash—Paclitaxel—breast cancer	1.78e-06	4.16e-05	CcSEcCtD
Epirubicin—Dermatitis—Paclitaxel—breast cancer	1.78e-06	4.16e-05	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—breast cancer	1.78e-06	4.16e-05	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—breast cancer	1.77e-06	4.16e-05	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—breast cancer	1.77e-06	4.14e-05	CcSEcCtD
Epirubicin—Headache—Paclitaxel—breast cancer	1.77e-06	4.14e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Docetaxel—breast cancer	1.76e-06	4.12e-05	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—breast cancer	1.76e-06	4.11e-05	CcSEcCtD
Epirubicin—Confusional state—Methotrexate—breast cancer	1.74e-06	4.07e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—breast cancer	1.72e-06	4.03e-05	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—breast cancer	1.72e-06	4.03e-05	CcSEcCtD
Epirubicin—Asthenia—Docetaxel—breast cancer	1.71e-06	4.01e-05	CcSEcCtD
Epirubicin—Infection—Methotrexate—breast cancer	1.71e-06	4.01e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Capecitabine—breast cancer	1.7e-06	3.99e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—breast cancer	1.7e-06	3.97e-05	CcSEcCtD
Epirubicin—Pruritus—Docetaxel—breast cancer	1.69e-06	3.96e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—breast cancer	1.69e-06	3.96e-05	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—breast cancer	1.69e-06	3.95e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—breast cancer	1.69e-06	3.95e-05	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—breast cancer	1.68e-06	3.93e-05	CcSEcCtD
Epirubicin—Nausea—Paclitaxel—breast cancer	1.67e-06	3.92e-05	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—breast cancer	1.67e-06	3.92e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—breast cancer	1.67e-06	3.9e-05	CcSEcCtD
Epirubicin—Asthenia—Capecitabine—breast cancer	1.66e-06	3.89e-05	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—breast cancer	1.65e-06	3.86e-05	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—breast cancer	1.64e-06	3.84e-05	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—breast cancer	1.64e-06	3.84e-05	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—breast cancer	1.64e-06	3.84e-05	CcSEcCtD
Epirubicin—Pruritus—Capecitabine—breast cancer	1.64e-06	3.83e-05	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—breast cancer	1.64e-06	3.83e-05	CcSEcCtD
Epirubicin—Diarrhoea—Docetaxel—breast cancer	1.64e-06	3.83e-05	CcSEcCtD
Epirubicin—Palpitations—Doxorubicin—breast cancer	1.61e-06	3.78e-05	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—breast cancer	1.61e-06	3.77e-05	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—breast cancer	1.61e-06	3.76e-05	CcSEcCtD
Epirubicin—Cough—Doxorubicin—breast cancer	1.59e-06	3.73e-05	CcSEcCtD
Epirubicin—Convulsion—Doxorubicin—breast cancer	1.58e-06	3.71e-05	CcSEcCtD
Epirubicin—Diarrhoea—Capecitabine—breast cancer	1.58e-06	3.71e-05	CcSEcCtD
Epirubicin—Dizziness—Docetaxel—breast cancer	1.58e-06	3.7e-05	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—breast cancer	1.58e-06	3.69e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—breast cancer	1.57e-06	3.67e-05	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—breast cancer	1.56e-06	3.65e-05	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—breast cancer	1.56e-06	3.64e-05	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—breast cancer	1.56e-06	3.64e-05	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—breast cancer	1.56e-06	3.64e-05	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—breast cancer	1.55e-06	3.63e-05	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—breast cancer	1.55e-06	3.62e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.55e-06	3.62e-05	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—breast cancer	1.54e-06	3.6e-05	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—breast cancer	1.54e-06	3.6e-05	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—breast cancer	1.53e-06	3.59e-05	CcSEcCtD
Epirubicin—Dizziness—Capecitabine—breast cancer	1.53e-06	3.58e-05	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—breast cancer	1.52e-06	3.56e-05	CcSEcCtD
Epirubicin—Vomiting—Docetaxel—breast cancer	1.52e-06	3.56e-05	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—breast cancer	1.52e-06	3.55e-05	CcSEcCtD
Epirubicin—Rash—Docetaxel—breast cancer	1.51e-06	3.53e-05	CcSEcCtD
Epirubicin—Dermatitis—Docetaxel—breast cancer	1.51e-06	3.52e-05	CcSEcCtD
Epirubicin—Confusional state—Doxorubicin—breast cancer	1.5e-06	3.52e-05	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—breast cancer	1.5e-06	3.51e-05	CcSEcCtD
Epirubicin—Headache—Docetaxel—breast cancer	1.5e-06	3.51e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—breast cancer	1.49e-06	3.49e-05	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—breast cancer	1.49e-06	3.49e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—breast cancer	1.49e-06	3.48e-05	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—breast cancer	1.48e-06	3.48e-05	CcSEcCtD
Epirubicin—Infection—Doxorubicin—breast cancer	1.48e-06	3.47e-05	CcSEcCtD
Epirubicin—Pain—Methotrexate—breast cancer	1.47e-06	3.45e-05	CcSEcCtD
Epirubicin—Vomiting—Capecitabine—breast cancer	1.47e-06	3.44e-05	CcSEcCtD
Epirubicin—Shock—Doxorubicin—breast cancer	1.47e-06	3.44e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—breast cancer	1.46e-06	3.42e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—breast cancer	1.46e-06	3.42e-05	CcSEcCtD
Epirubicin—Rash—Capecitabine—breast cancer	1.46e-06	3.42e-05	CcSEcCtD
Epirubicin—Dermatitis—Capecitabine—breast cancer	1.46e-06	3.41e-05	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—breast cancer	1.46e-06	3.41e-05	CcSEcCtD
Epirubicin—Headache—Capecitabine—breast cancer	1.45e-06	3.39e-05	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—breast cancer	1.45e-06	3.39e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—breast cancer	1.44e-06	3.38e-05	CcSEcCtD
Epirubicin—Anorexia—Doxorubicin—breast cancer	1.42e-06	3.33e-05	CcSEcCtD
Epirubicin—Nausea—Docetaxel—breast cancer	1.42e-06	3.32e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Methotrexate—breast cancer	1.42e-06	3.32e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—breast cancer	1.41e-06	3.3e-05	CcSEcCtD
Epirubicin—Hypotension—Doxorubicin—breast cancer	1.39e-06	3.26e-05	CcSEcCtD
Epirubicin—Nausea—Capecitabine—breast cancer	1.37e-06	3.22e-05	CcSEcCtD
Epirubicin—Urticaria—Methotrexate—breast cancer	1.37e-06	3.2e-05	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—breast cancer	1.36e-06	3.19e-05	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—breast cancer	1.36e-06	3.19e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.36e-06	3.18e-05	CcSEcCtD
Epirubicin—Insomnia—Doxorubicin—breast cancer	1.35e-06	3.16e-05	CcSEcCtD
Epirubicin—Paraesthesia—Doxorubicin—breast cancer	1.34e-06	3.14e-05	CcSEcCtD
Epirubicin—Dyspnoea—Doxorubicin—breast cancer	1.33e-06	3.11e-05	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—breast cancer	1.33e-06	3.1e-05	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—breast cancer	1.31e-06	3.07e-05	CcSEcCtD
Epirubicin—Decreased appetite—Doxorubicin—breast cancer	1.3e-06	3.04e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—breast cancer	1.29e-06	3.01e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—breast cancer	1.29e-06	3.01e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—breast cancer	1.28e-06	2.99e-05	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—breast cancer	1.28e-06	2.99e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Methotrexate—breast cancer	1.27e-06	2.97e-05	CcSEcCtD
Epirubicin—Asthenia—Methotrexate—breast cancer	1.24e-06	2.89e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Doxorubicin—breast cancer	1.23e-06	2.88e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—breast cancer	1.22e-06	2.86e-05	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—breast cancer	1.22e-06	2.85e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MAPK3—breast cancer	1.2e-06	5.82e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SRC—breast cancer	1.19e-06	5.8e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ADAM10—breast cancer	1.19e-06	5.78e-05	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—breast cancer	1.18e-06	2.77e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—RPS6—breast cancer	1.18e-06	5.75e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—COMT—breast cancer	1.18e-06	5.75e-05	CbGpPWpGaD
Epirubicin—Abdominal pain—Doxorubicin—breast cancer	1.18e-06	2.76e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—breast cancer	1.18e-06	2.76e-05	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—breast cancer	1.18e-06	2.76e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—GSTP1—breast cancer	1.18e-06	5.72e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGF4—breast cancer	1.17e-06	5.71e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.17e-06	5.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL12—breast cancer	1.17e-06	5.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCR4—breast cancer	1.17e-06	5.69e-05	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ALB—breast cancer	1.17e-06	5.67e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—breast cancer	1.16e-06	5.66e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—FASN—breast cancer	1.16e-06	5.66e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—breast cancer	1.16e-06	5.65e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—HMOX1—breast cancer	1.16e-06	5.64e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—COMT—breast cancer	1.16e-06	5.64e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—BCHE—breast cancer	1.16e-06	5.63e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ITPR1—breast cancer	1.16e-06	5.63e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGF10—breast cancer	1.16e-06	5.63e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTP1—breast cancer	1.15e-06	5.61e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PAK1—breast cancer	1.15e-06	5.58e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SLC5A5—breast cancer	1.14e-06	5.56e-05	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—breast cancer	1.14e-06	2.67e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—HMOX1—breast cancer	1.14e-06	5.53e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ITPR1—breast cancer	1.14e-06	5.52e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TCF7L2—breast cancer	1.13e-06	5.48e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PDGFA—breast cancer	1.12e-06	5.43e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CG—breast cancer	1.11e-06	5.42e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ABCB1—breast cancer	1.11e-06	5.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NQO1—breast cancer	1.11e-06	5.37e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SLC2A1—breast cancer	1.11e-06	5.37e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFBR2—breast cancer	1.1e-06	5.35e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—MAPK3—breast cancer	1.1e-06	5.34e-05	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—breast cancer	1.1e-06	2.57e-05	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—breast cancer	1.1e-06	2.56e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—TYMS—breast cancer	1.09e-06	5.32e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ABCB1—breast cancer	1.09e-06	5.31e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH2—breast cancer	1.09e-06	5.29e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HSP90AA1—breast cancer	1.09e-06	5.29e-05	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CA—breast cancer	1.09e-06	5.28e-05	CbGpPWpGaD
Epirubicin—Rash—Methotrexate—breast cancer	1.09e-06	2.54e-05	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—breast cancer	1.08e-06	2.54e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—ITPR1—breast cancer	1.08e-06	5.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.08e-06	5.26e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTM1—breast cancer	1.08e-06	5.26e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NCOR1—breast cancer	1.08e-06	5.26e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PLA2G4A—breast cancer	1.08e-06	5.26e-05	CbGpPWpGaD
Epirubicin—Headache—Methotrexate—breast cancer	1.08e-06	2.53e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP3A4—breast cancer	1.08e-06	5.24e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB4—breast cancer	1.08e-06	5.23e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT5A—breast cancer	1.08e-06	5.23e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TYMS—breast cancer	1.07e-06	5.21e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.07e-06	5.21e-05	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—breast cancer	1.07e-06	2.51e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—breast cancer	1.07e-06	5.18e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NCOR1—breast cancer	1.06e-06	5.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTM1—breast cancer	1.06e-06	5.15e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP1B1—breast cancer	1.06e-06	5.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PRL—breast cancer	1.06e-06	5.14e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AGTR1—breast cancer	1.06e-06	5.14e-05	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—breast cancer	1.06e-06	2.47e-05	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—RAF1—breast cancer	1.05e-06	5.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ADAM10—breast cancer	1.04e-06	5.07e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STK11—breast cancer	1.04e-06	5.07e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SMAD4—breast cancer	1.04e-06	5.07e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—HSP90AA1—breast cancer	1.04e-06	5.05e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GPX1—breast cancer	1.04e-06	5.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PLG—breast cancer	1.03e-06	5.01e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP1A1—breast cancer	1.03e-06	4.98e-05	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—breast cancer	1.02e-06	2.4e-05	CcSEcCtD
Epirubicin—Diarrhoea—Doxorubicin—breast cancer	1.02e-06	2.39e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT2—breast cancer	1.02e-06	4.96e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HES1—breast cancer	1.02e-06	4.95e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ERCC2—breast cancer	1.02e-06	4.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GPX1—breast cancer	1.02e-06	4.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGF10—breast cancer	1.01e-06	4.93e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NCOR1—breast cancer	1.01e-06	4.92e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOA1—breast cancer	1.01e-06	4.91e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP1A1—breast cancer	1.01e-06	4.89e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGF1—breast cancer	1e-06	4.86e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ERCC2—breast cancer	9.97e-07	4.85e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—STK11—breast cancer	9.97e-07	4.84e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP19A1—breast cancer	9.97e-07	4.84e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRG1—breast cancer	9.93e-07	4.83e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—breast cancer	9.87e-07	4.8e-05	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—breast cancer	9.86e-07	2.31e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—H2AFX—breast cancer	9.86e-07	4.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CD—breast cancer	9.8e-07	4.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFA—breast cancer	9.79e-07	4.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFBR2—breast cancer	9.65e-07	4.69e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—breast cancer	9.56e-07	4.65e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—MTHFR—breast cancer	9.56e-07	4.64e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERCC2—breast cancer	9.51e-07	4.62e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ITPR1—breast cancer	9.5e-07	4.61e-05	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—breast cancer	9.48e-07	2.22e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—STAT5A—breast cancer	9.43e-07	4.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB4—breast cancer	9.43e-07	4.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP3—breast cancer	9.43e-07	4.58e-05	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—breast cancer	9.4e-07	2.2e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—breast cancer	9.39e-07	2.2e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—MTHFR—breast cancer	9.37e-07	4.56e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—breast cancer	9.35e-07	4.55e-05	CbGpPWpGaD
Epirubicin—Headache—Doxorubicin—breast cancer	9.34e-07	2.19e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—ERBB3—breast cancer	9.3e-07	4.52e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGFR2—breast cancer	9.29e-07	4.51e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—COMT—breast cancer	9.26e-07	4.5e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTP1—breast cancer	9.22e-07	4.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMAD4—breast cancer	9.13e-07	4.44e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—HMOX1—breast cancer	9.09e-07	4.42e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1R—breast cancer	9.08e-07	4.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ITPR1—breast cancer	9.07e-07	4.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—breast cancer	9.07e-07	4.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTHFR—breast cancer	8.94e-07	4.35e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HES1—breast cancer	8.92e-07	4.33e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—breast cancer	8.92e-07	4.33e-05	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKT1—breast cancer	8.88e-07	4.31e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NCOR1—breast cancer	8.87e-07	4.31e-05	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—breast cancer	8.86e-07	2.07e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CAV1—breast cancer	8.82e-07	4.28e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—breast cancer	8.78e-07	4.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGF1—breast cancer	8.77e-07	4.26e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CSF2—breast cancer	8.77e-07	4.26e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—RAF1—breast cancer	8.75e-07	4.25e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ABCB1—breast cancer	8.73e-07	4.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRG1—breast cancer	8.7e-07	4.23e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGFR1—breast cancer	8.66e-07	4.21e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CAV1—breast cancer	8.65e-07	4.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—H2AFX—breast cancer	8.64e-07	4.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—E2F1—breast cancer	8.58e-07	4.17e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TYMS—breast cancer	8.57e-07	4.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CB—breast cancer	8.54e-07	4.15e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HIF1A—breast cancer	8.53e-07	4.14e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTM1—breast cancer	8.47e-07	4.12e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PLA2G4A—breast cancer	8.47e-07	4.12e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOR1—breast cancer	8.47e-07	4.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—breast cancer	8.39e-07	4.08e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.26e-07	4.01e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CAV1—breast cancer	8.25e-07	4.01e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SPP1—breast cancer	8.24e-07	4.01e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—breast cancer	8.21e-07	3.99e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB3—breast cancer	8.15e-07	3.96e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR2—breast cancer	8.14e-07	3.96e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GPX1—breast cancer	8.11e-07	3.94e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP1A1—breast cancer	8.03e-07	3.9e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CG—breast cancer	8.03e-07	3.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ERCC2—breast cancer	7.97e-07	3.87e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CG—breast cancer	7.87e-07	3.83e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—breast cancer	7.84e-07	3.81e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—breast cancer	7.82e-07	3.8e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOS2—breast cancer	7.76e-07	3.77e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOTCH1—breast cancer	7.68e-07	3.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR1—breast cancer	7.59e-07	3.69e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KIT—breast cancer	7.51e-07	3.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APC—breast cancer	7.51e-07	3.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—MTHFR—breast cancer	7.49e-07	3.64e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HIF1A—breast cancer	7.47e-07	3.63e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGF—breast cancer	7.43e-07	3.61e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—breast cancer	7.41e-07	3.6e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—LEP—breast cancer	7.3e-07	3.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CAV1—breast cancer	7.23e-07	3.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KDR—breast cancer	7.15e-07	3.47e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BRAF—breast cancer	7.06e-07	3.43e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CD—breast cancer	7.06e-07	3.43e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ALB—breast cancer	6.97e-07	3.39e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ESR1—breast cancer	6.97e-07	3.39e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CD—breast cancer	6.92e-07	3.36e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CAV1—breast cancer	6.91e-07	3.36e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FN1—breast cancer	6.88e-07	3.34e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT2—breast cancer	6.87e-07	3.34e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ALB—breast cancer	6.83e-07	3.32e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NFKBIA—breast cancer	6.8e-07	3.3e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH1—breast cancer	6.73e-07	3.27e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NOS3—breast cancer	6.67e-07	3.24e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CD—breast cancer	6.6e-07	3.21e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.6e-07	3.21e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APC—breast cancer	6.58e-07	3.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CG—breast cancer	6.58e-07	3.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIT—breast cancer	6.58e-07	3.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NOS3—breast cancer	6.54e-07	3.18e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SERPINE1—breast cancer	6.53e-07	3.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGF—breast cancer	6.51e-07	3.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAPK3—breast cancer	6.31e-07	3.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CG—breast cancer	6.29e-07	3.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOS3—breast cancer	6.24e-07	3.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BRAF—breast cancer	6.19e-07	3.01e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CB—breast cancer	6.15e-07	2.99e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—breast cancer	6.1e-07	2.96e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CB—breast cancer	6.03e-07	2.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1—breast cancer	6.03e-07	2.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT2—breast cancer	6.02e-07	2.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—breast cancer	6e-07	2.92e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—breast cancer	5.98e-07	2.91e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MDM2—breast cancer	5.92e-07	2.88e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—RAF1—breast cancer	5.9e-07	2.87e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB2—breast cancer	5.83e-07	2.84e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CD—breast cancer	5.79e-07	2.81e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTOR—breast cancer	5.76e-07	2.8e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CB—breast cancer	5.76e-07	2.8e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD4—breast cancer	5.75e-07	2.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SERPINE1—breast cancer	5.73e-07	2.78e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—breast cancer	5.7e-07	2.77e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—breast cancer	5.67e-07	2.75e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CD—breast cancer	5.53e-07	2.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOS3—breast cancer	5.47e-07	2.66e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ALB—breast cancer	5.46e-07	2.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1B—breast cancer	5.4e-07	2.63e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—breast cancer	5.32e-07	2.58e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NOS3—breast cancer	5.22e-07	2.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—breast cancer	5.21e-07	2.53e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—breast cancer	5.21e-07	2.53e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—breast cancer	5.19e-07	2.52e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RAF1—breast cancer	5.17e-07	2.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RELA—breast cancer	5.14e-07	2.5e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB2—breast cancer	5.11e-07	2.48e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—breast cancer	5.1e-07	2.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CB—breast cancer	5.05e-07	2.45e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MTOR—breast cancer	5.05e-07	2.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1A—breast cancer	4.99e-07	2.42e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—breast cancer	4.97e-07	2.42e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—breast cancer	4.85e-07	2.36e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CB—breast cancer	4.82e-07	2.34e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—breast cancer	4.82e-07	2.34e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—breast cancer	4.78e-07	2.32e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1B—breast cancer	4.73e-07	2.3e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—breast cancer	4.64e-07	2.26e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—breast cancer	4.63e-07	2.25e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—breast cancer	4.61e-07	2.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—breast cancer	4.61e-07	2.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—breast cancer	4.52e-07	2.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUN—breast cancer	4.51e-07	2.19e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—breast cancer	4.47e-07	2.17e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—breast cancer	4.45e-07	2.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—breast cancer	4.39e-07	2.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1A—breast cancer	4.37e-07	2.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—breast cancer	4.36e-07	2.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK8—breast cancer	4.26e-07	2.07e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—breast cancer	4.25e-07	2.07e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAPK3—breast cancer	4.25e-07	2.07e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—breast cancer	4.17e-07	2.02e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—breast cancer	4.13e-07	2.01e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—breast cancer	4.12e-07	2e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—breast cancer	4.04e-07	1.97e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—breast cancer	4.04e-07	1.96e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—breast cancer	3.94e-07	1.91e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—breast cancer	3.9e-07	1.89e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—breast cancer	3.82e-07	1.86e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—breast cancer	3.75e-07	1.82e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK3—breast cancer	3.73e-07	1.81e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—breast cancer	3.68e-07	1.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—breast cancer	3.62e-07	1.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—breast cancer	3.61e-07	1.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—breast cancer	3.54e-07	1.72e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—breast cancer	3.51e-07	1.71e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—breast cancer	3.35e-07	1.63e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—breast cancer	3.25e-07	1.58e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—breast cancer	3.11e-07	1.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—breast cancer	3.08e-07	1.49e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—breast cancer	3.06e-07	1.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—breast cancer	3e-07	1.46e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—breast cancer	2.98e-07	1.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—breast cancer	2.94e-07	1.43e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—breast cancer	2.87e-07	1.39e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—breast cancer	2.85e-07	1.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—breast cancer	2.72e-07	1.32e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—breast cancer	2.51e-07	1.22e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—breast cancer	2.4e-07	1.17e-05	CbGpPWpGaD
